Agnieszka Glebocka

This inventor holds 18 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Vitamin D Analog Development. Top assignees: Wisconsin Alumni Research Foundation, Arrowhead Pharmaceuticals, Inc.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Agnieszka Glebocka. Retrieved from https://idiyas.com/inventor/agnieszka-glebocka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 14)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 26(Granted Patents)

Location History:

Warsaw, PL (2007 - 2011)
Madison, WI (US) (2009 - 2021)

Company Filing History:

11 out of 4,243

Wisconsin Alumni Research Foundation

patents

7 out of 102

Arrowhead Pharmaceuticals, Inc.

patents

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

RNAi Agents

Microtubule Associated Protein Tau

Transferrin Receptor Antibodies

Alpha-v Beta-6 Integrin

Targeting Ligands

Vitamin D Analogs

Compositions

Therapeutic Uses

Crystallization

Cyclopentene Ring

Hydroxypropylidene Compounds

Dihydrofuran Ring

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12551569 - RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use (2026-02-17),

2. 12527877 - ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF (2026-01-20),

3. 12442002 - RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use (2025-10-14),

4. 12173086 - Alpha-v beta-6 integrin ligands and uses thereof (2024-12-24),

5. 11180529 - Alpha-v beta-6 integrin ligands and uses thereof (2021-11-23),

6. 11174481 - Targeting ligands (2021-11-16),

7. 10294474 - Targeting ligands (2019-05-21),

8. 8785422 - A-ring modified 19-nor-vitamin D analogs and their uses (2014-07-22),

9. 8519169 - Crystallization a 1alpha-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D3 (2013-08-27),

10. 8217023 - 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring (2012-07-10),

11. 8058265 - 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof (2011-11-15),

12. 7943601 - 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs (2011-05-17),

13. 7879829 - 19-nor-vitamin D analogs with 1,2-dihydrofuran ring (2011-02-01),

14. 7763598 - 1α-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain (2010-07-27),

15. 7648974 - 19-nor-vitamin D analogs with 3,2-dihydrofuran ring (2010-01-19),

Title: Agnieszka Glebocka: Innovator in RNAi Therapeutics

Introduction

Agnieszka Glebocka is a prominent inventor based in Madison, Wisconsin, known for her significant contributions to the field of RNA interference (RNAi) therapeutics. With a total of 16 patents to her name, she has made remarkable strides in developing innovative solutions for various health conditions.

Latest Patents

Among her latest patents, Glebocka has developed RNAi agents for inhibiting the expression of activin receptor-like kinase 7 (ALK7). These agents, along with their compositions and methods of use, provide a novel approach to inhibit the ALK7 gene. The ALK7 RNAi agents and conjugates disclosed in her patents are designed to reduce ALK7 activity, offering potential therapeutic benefits for conditions such as obesity, diabetes, and insulin resistance. Additionally, she has worked on integrin ligands that exhibit serum stability and affinity for αvβ6 integrins, further expanding her impact in the field.

Career Highlights

Glebocka has held key positions at notable organizations, including the Wisconsin Alumni Research Foundation and Arrowhead Pharmaceuticals, Inc. Her work has been instrumental in advancing the understanding and application of RNAi technologies in therapeutic settings.

Collaborations

Throughout her career, Glebocka has collaborated with esteemed colleagues, including Hector Floyd Deluca and Lori A. Plum. These partnerships have contributed to her innovative research and development efforts.

Conclusion

Agnieszka Glebocka's work exemplifies the intersection of innovation and healthcare, particularly in the realm of RNAi therapeutics. Her contributions continue to pave the way for advancements in treating complex diseases.

Profile summary based on public USPTO records.